WO2025163581 - CD8-BINDING CYTOKINE ENGAGERS AND METHODS OF USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/163581
Publication Date
07.08.2025
International Application No.
PCT/IB2025/051070
International Filing Date
31.01.2025
Title **
[English]
CD8-BINDING CYTOKINE ENGAGERS AND METHODS OF USE THEREOF
[French]
AGENTS ENGAGEURS DE CYTOKINE SE LIANT À CD8 ET LEURS PROCÉDÉS D'UTILISATION
Applicants **
ASTRAZENECA AB
Inventors
ELDER, Matthew
RILEY, Aidan
OROZCO, Carolina
MASTIO, Jerome
TAN, Sin Lih
FREDERICO, Bruno
CHEN, Hung-Chang
DOVEDI, Simon
COLLINSON, Andie
CARLESSO, Gianluca
STEINHARDT, James
CEMERSKI, Saso
RIGGS, Jeffrey
Priority Data
63/627,948
01.02.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3298 | |
| EPO | Filing, Examination, Granting | 21899 | |
| Japan | Filing, Examination, Granting | 2868 | |
| South Korea | Filing, Examination, Granting | 3393 | |
| USA | Filing, Examination, Granting | 10390 |
Total:
41,848
Contact Us
Abstract[English]
The disclosure provides a cytokine engager comprising an antibody that specifically bind human CD8, and wherein the antibody is fused to a cytokine (e.g., IL-2). Compositions and Methods of administering the compositions to preferentially expand T cells and treat cancer are also provided.[French]
L'invention concerne un agent engageur de cytokine comprenant un anticorps qui se lie spécifiquement au CD8 humain, l'anticorps étant en outre fusionné à une cytokine (par exemple, l'IL-2). L'invention concerne également des compositions et des méthodes d'administration des compositions, de préférence en vue de l'expansion de lymphocytes T et du traitement d'un cancer.